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Abstract: Tenofovir disoproxil fumarate (TDF) has low general toxicity and can lead to a 
moderate reduction in glomerular filtration rate (GFR) and a more significant prevalence 
of renal tubular dysfunction (RTD). The mechanism of RTD has been attributed to the 
mitochondrial lesion in the proximal tubule cells caused by the increase of the intracellular 
TDF concentration. Additionally, the host's genetic polymorphisms have been considered 
one of the TDF concentration increasing causes. RTD can be characterized by the 
deficiency in the solutes reabsorption as bicarbonate, uric acid, phosphate, glucose, and 
low weight molecular proteins. Research Objectives: verify the prevalence of renal 
tubular dysfunction in people living with HIV (PLWH) on TDF treatment, identify the risk 
factors associated and compare the 24-hour urine findings with the serum creatinine and 
its calculated clearance for the RTD identification. Research methods: prospective case-
control study, performed between January 2011 to December 2015. Research 
results: 163 patients were included in the study, in which 106 (68.4%) did not receive 
TDF, and 57 (31.6%) received TDF. RTD occurred in 8 patients that used TDF, a 
prevalence of 14%. The patient's age was identified as a significant risk factor for the 
development of RTD. Proteinuria and phosphaturia were substantial for the diagnosis of 
RTD. Conclusions: age was considered as a risk factor for RTD, mainly in patients over 
60-year-old. Phosphaturia and proteinuria showed the highest diagnosis sensitivity for 
RTD. The serum creatinine and phosphorus concentration, the creatinine clearance, and 
the stand-alone hyperproteinuria should not be considered as diagnosis predictors for 
RTD. 
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INTRODUCTION 
 Currently, HIV (Human Immunodeficiency Virus) is a chronic and relatively 
controlled disease. However, its new challenges are clinical conditions secondary to 
antiretroviral therapy (ART), the presence of HIV and its chronic inflammatory activity, 
early aging, genetic predisposition and patient's life habits1,2,3. 
 Although ART reduces AIDS (acquired immunodeficiency syndrome) mortality and 
increases the life expectancy of HIV-infected individuals, it may contribute to the onset of 
long-term adverse effects, including kidney disease. Tenofovir disoproxil fumarate (TDF), 
is considered a first-line antiretroviral treatment because of its general toxicity. However 
it can lead to a moderate reduction in the glomerular filtration rate (GFR) and a higher 
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prevalence of renal tubular dysfunction (RTD) in patients who received TDF compared 
with those who did not4. Decreased renal function in patients may be acute or chronic9. 
 The RTD mechanism is not completely understood, it might be attributed to 
mitochondrial lesions in proximal tubule cells as a result of an increase in intracellular 
TDF concentration and the potential influence of genetic polymorphisms5. The RTD is 
characterized by a deficiency in the reabsorption of solutes such as bicarbonate, uric acid, 
phosphate, glucose, and low molecular weight proteins6. 
 The proximal tubule (PT) is primarily responsible for the excretion of TDF. Its 
dysfunction leads to the loss of substances through urine, which is normally filtered in the 
glomeruli and reabsorbed by the tubular portion. TDF's tubular secretion occurs via 
organic anion transport in the PT using specific transporters located in the basal and 
apical membranes of tubular cells. Uptake from the bloodstream occurs through human 
anion organic transporter types 1 and 3, located in the basolateral portion of the cell. 
Secretion to the tubular lumen occurs through multidrug resistance-associated protein 
(MRP) types 2, 4, and 7, which locates in the apical portion of the cell. The MRPs are 
encoded by the genes ABCC2, ABCC4, and ABCC105,11,12. 
 Originally, TDF nephrotoxicity was described as the manifestation of Fanconi 
syndrome, a tubular disease characterized by phosphaturia, aminoaciduria, uricosuria, 
and glycosuria not associated with hyperglycemia8. Subsequently, to characterize TDF 
nephrotoxicity as RTD, new studies have suggested the presence of at least two tubular 
abnormalities, such as hyperphosphaturia, glycosuria without hyperglycemia, 
hyperuricosuria, hypophosphatemia and/or proteinuria4,6. 
 In renal biopsy analysis of patients on TDF treatment, the main finding is PT 
lesions, which can be severe and diffuse or moderate and localized, combined with 
variable degrees of chronic tubular atrophy and interstitial fibrosis. No focal segmental 
glomerulosclerosis or tubular microcysts, typical of HIV-associated nephropathy, have 
been found7. 
 Risk factors associated with RTD have high variability. It has been suggested that 
age, being an attenuated patient with low weight, hypertension, metabolic disorders, 
simultaneous use of other nephrotoxic medications, and TDF administration combined 
with ritonavir-boosted protease inhibitors (IP/r) are important risk factors8. 
 The novelty of this research is the evaluation of RTD, excluding patients with 
glomerulopathies and HIV-associated nephropathy due to detectable viral load. This 
research aims to verify the prevalence of RTD in the people living with HIV (PLWH) on 
TDF treatment, identify the risk factors associated with RTD and compare the 24-hour 
urine findings with the serum creatinine and its calculated clearance for the RTD 
identification.  
 
MATERIALS AND METHODS 
 This research was a case-control longitudinal study conducted at a specialized 
outpatient clinic in the State of São Paulo. HIV-infected patients receiving ART were 
followed up at a medical center from January 2011 to December 2015. The inclusion 
criteria was: HIV patients using TDF with undetectable viral load (VL) (less than 20 
copies/mL of blood). The exclusion criteria was: HIV infected with other types of 
nephropathy. 




Definition of cases and controls: To assess risk factors associated with RTD, 
patients were divided into two groups; patients on ART with TDF (exposed patients) and 
those on ART without TDF (non-exposed patients). Exposed and non-exposed patients 
were studied in regards to exposure to independent variables assumed to be risk factors. 
Exposed individuals were those on ART with TDF until RTD development. Non-exposed 
individuals were those on ART without TDF. 
Renal tubular dysfunction: RTD is defined as generalized proximal tubulopathy that 
combines the presence of at least one of the following alterations; hypophosphatemia, 
hyperphosphaturia, glycosuria without hyperglycemia and tubular proteinuria. That 
occurs due to the use of TDF in combination with other antiretroviral drugs. 
Laboratory tests: Blood samples for the T-CD4 lymphocyte count and HIV VL count 
were performed every six months throughout treatment. Blood samples for serum 
creatinine test was collected at the beginning of the treatment and once annually 
throughout follow-up. Twenty-four-hour urine and serum phosphorus were collected once 
annually in the monitoring of ART with TDF. 
Continuous numerical variables studied as risk factors were age, time of HIV 
infection, T-CD4 lymphocyte level, total time on ART, time on ART with TDF, initial serum 
creatinine, initial creatinine clearance, creatinine at RTD diagnosis, serum phosphorus at 
RTD diagnosis and 24-hour urine (proteinuria, phosphaturia and creatinine clearance) at 
RTD diagnosis. Gender was considered a dichotomous (present or absent) risk factor. 
The statistical analysis used in this study were as follows t-Student test, Pearson 
chi-square test, Odds ration, Exponential Distribution, Kolmogorov-Smirnov normality 
test, ANOVA test, and Levene's Homogeneity Test. 
 This study was approved by the ethical committee of the Faculdade de Medicina 
de São José do Rio Preto – FAMERP - reference number 1.573.409 and also performed 
under the 1964 Helsinki declaration and its later amendments or comparable ethical 
standards. 
 
RESULT AND DISCUSSION 
 A total of 163 patients were included in the study. One hundred and six patients 
(68.4%) were not on TDF treatment (non-TDF group), and 57 (31.6%) were on TDF 
treatment (TDF group). RTD occurred in 8 patients in the TDF group, indicating a 
prevalence of 14% (Table 1). 
 
Table 1. Distribution of Patients in the TDF and Non-TDF Groups and RTD Prevalence. 
 
   RTD    
   Not applicable   Yes   Total   P *  
Non-TDF   n  106 0 106 0.000  
100.0% 0.0% 100.0%  
TDF   n  49 8 57 0.000   
86.0% 14.0% 100.0% 
 
RTD: renal tubular dysfunction; TDF: tenofovir. 
* Pearson chi-square test (p <0.01). 
 




Patient age ranged from 20 to 75 year-old, with a mean age of 43.9 years ± 10.9 (p 
= 0.01 in the univariate analysis and logistic regression) (Tables 2 and 3).  
 
Table 2. Distribution of Demographic, Clinical, and Laboratory Variables as Risk Factors 
for the Development of RTD. 
 








Limit   P *  
Age  43.93 42.24 45.61 10.913 0.011 
Time with contagion (months)  105.02 93.46 116.58 74.749 0.481 
Current CD4 count (cells/mm3) 550.82 511.89 589.75 250.899 0.415 
Total time on ART (months)  81.53 71.69 91.38 63.656 0.579 
Time on ART with TDF (months)  55.42 48.62 62.23 43.999 0.319 
CI: confidence interval. 
* Univariate analysis, ANOVA test (p <0.05). 
 
Table 3. Logistic Regression of Demographic, Clinical, and Laboratory Variables, 
Analysed as Risk Factors for the Development of RTD. 
 
Variables  Coefficient   P   OR  
Sex (1) 0.190 0.819 1.209 
Age  0.089 0.016 1.093 
Time with contagion (months)  0.003 0.708 1.003 
Current CD4 count (cells/mm3) -0.001 0.588 0.999 
Total time on ART (months)  -0.001 0.953 0.999 
Time on ART with TDF (months)  -0.017 0.168 0.983 
 1: female; OR: odds ratio. 
 
For each year, the risk for developing RTD was 9% (Table 3). For people over 60 year-
old, the risk for developing RTD was 14 times higher than those people in the group 
younger than 60 year-old (Table 4). 
 
Table 4. Logistic Regression of Demographic, Clinical, and Laboratory Variables, by 
Range, Analyzed as Risk Factors for the Development of RTD. 
 
Variables  Coefficient   P   OR  
Sex (1) 0.347 0.676 1.414 
Age range (2) 2.646 0.004 14.091 
Time with contagion (months)  0.005 0.543 1.005 
Current CD4 range (3) -1.270 0.174 0.281 
Total time on ART (months)  0.004 0.666 1.004 
Time on ART (months)  -0.019 0.128 0.981 
1: female; 2: age range > 60 years old. 3: CD4 > 500 cells/mm3. 
OR: odds ratio. 
 




 Age was identified as a significant risk factor for the development of RTD (Tables 
2 and 3). Initial serum creatinine ranged from 0.40 mg/dL to 1.30 mg/dL, with a mean of 
0.88 mg/dL ± 0.19 (p = 0.96, and the serum creatinine level at RTD diagnosis was 0.82 
mg/dL ± 0.21 (p = 0.001) (Table 5). The comparison of initial and current (at RTD 
diagnosis) serum creatinine levels showed a reduction in serum creatinine levels at RTD 
diagnosis (p = 0.002) (Table 6). 
   
Table 5. Distribution of Laboratory Variables, Analyzed as Diagnostic Criteria for RTD, 
in the TDF Group. 
 
 
 95% CI   






deviation   P *  
Initial creatinine (mg/dL) RV 0.4 to 
1.3 mg/dL  
0.8853 0.8554 0.9151 0.19305 0.967 
Current (at RTD diagnosis) 
creatinine (mg/dL) RV 0.4 to 1.3 
mg/dL  
0.8216 0.7886 0.8546 0.21334 0.001 
Estimated initial creatinine 
clearance (mL/min) RV 70 to 140 
mL/min/1.73 m2   
107.39 103.56 111.22 24.771 0.040 
Current (at RTD diagnosis) 
creatinine clearance (mL/min) RV 
70 to 140 mL/min/1.73 m2  
114.59 108.04 121.14 42.360 0.015 
Current (at RTD diagnosis) 
phosphorus (mg/dL) RV 2.5 to 5.6 
mg/dL 
3.410 3.250 3.570 0.6207 0.089 
Current (at RTD diagnosis) 
proteinuria (mg/24 h) RV < 200 
mg/24 h 
109.29 91.54 127.03 68.097 0.125 
Current (at RTD diagnosis) 
phosphaturia (mg/24 h) RV 400 to 
1300 mg/24 h 
791.97 610.11 973.83 697.847 < 0.001 

















Table 6. Student's t-test for Analysis of Initial and Current (at RTD Diagnosis) Serum 












Current (at RTD diagnosis) 
creatinine (mg/dL) RV 0.4 to 
1.3 mg/dL - Initial creatinine 
(mg/dL) RV 0.4 to 1.3 mg/dL  
-0.06368 0.26175 -0.10417 -0.02320 0.002 
Current (at RTD diagnosis) 
creatinine clearance 
(ml/min), RV 70 to 140 
ml/min/1.73 m2 - Estimated 
initial creatinine clearance 
(ml/min), RV 70 to 140 
ml/min/1.73 m2  
7.202  40.192 0.986 13.419 0.023 
RV: reference value; p <0.01. 
 
 The estimated initial creatinine clearance, calculated by the Cockcroft-Gault 
formula, ranged from 26 mL/min to 205 mL/min, with a mean of 107 mL/min ± 24 (p = 
0.04) (Table 5). Current (at RTD diagnosis) creatinine clearance, evaluated via 24-h urine, 
ranged from 26 mL/min to 285 mL/min, with a mean of 114 mL/min ± 42.3 (p = 0.01) 
(Table 5). A comparison between current (at RTD diagnosis) and initial creatinine 
clearances did not indicate statistical significance (p = 0.02) (Table 6). 
 Only one patient exhibited abnormal serum phosphorus levels at RTD diagnosis 
(Table 7). Current (at RTD diagnosis) serum phosphorus ranged from 2.1 mg/dL to 4.9 
mg/dL, with a mean of 3.41 mg/dL ± 0.62, and was not significant (p = 0,296) (Table 8). 
  
Table 7. The Absolute Number of Patients with Changes in Current (at RTD Diagnosis) 
Phosphorus, Proteinuria, and Phosphaturia in the TDF Group. 
 
 
 RTD  
 Total n (%)   No n (%)   Yes n (%)  
 Phosphorus   There was no change  50 (96.15) 7 (87.5) 57 (95) 
 There was a change  2 (3.85) 1 (12.5) 3 (5)  
 Total (n)  52 (100) 8 (100) 60 (100) 
 Proteinuria   There was no change  47 (92.15) 5 (62.5) 52 (88.13) 
 There was a change  4 (7.85) 3 (37.5) 7 (11.87)  
 Total (n)  51 (100) 8 (100) 59 (100) 
 
Phosphaturia  
 There was no change  51 (100) 1 (14.28) 52 (88.13) 
 There was a change  0 (0) 7 (85.72) 7 (11.87)  
 Total (n)  51 (100) 8 (100) 59 
RTD: renal tubular dysfunction. 
 




Table 8. Pearson Chi-Square Test and Levene Homogeneity Test for The Analysis of 




Coefficient   P  
 Coefficient 
*   P *  
Current (at RTD diagnosis) 
phosphorus (mg/dL) RV 2.5 to 5.6 
mg/dL 
1.093 0.296 0.496 0.496 
Current (at RTD diagnosis) 
proteinuria (mg/24 h) RV < 200 
mg/24 h 
5.816 0.016 0.441 0.441 
Current (at RTD diagnosis) 
phosphaturia (mg/24 h) RV 400 to 
1300 mg/24 h 
50.632 0.000 0.000 < 0.001 
RV: reference value; p <0.01. 
* Levene homogeneity test, p <0.01. 
 
 Alteration in proteinuria was observed in 3 patients diagnosed with RTD (Table 8). 
Current (at RTD diagnosis) proteinuria, measured by the 24-hour urine, averaged 109.2 
mg/24 h ± 68 (p = 0.016), ranged from 29 mg/24 h to 367 mg/ 24 h and was significant 
for the diagnosis of RTD (Table 8). 
 Alteration in phosphaturia was observed in 7 patients at RTD diagnosis (Table 7). 
Current (at RTD diagnosis) phosphaturia, evaluated in 24-hour urine, ranged from 134 
mg/24 h to 5,254 mg/24 h, had a mean of 791.9 mg/24 h ± 697 (p < 0.01) and was 
significant for the diagnosis of RTD (Table 8). 
 This research was a case-control longitudinal study, performed along five years, 
in which patients with detectable HIV VL at any time were excluded and there was minimal 
inclusion of patients with comorbidities such as systemic arterial hypertension, diabetes 
mellitus and chronic hepatitis B and C. These diseases, if not controlled, and detectable 
HIV VL may cause undesirable mechanisms of renal injury for the adequate evaluation 
of RTD, thus preventing the accurate identification of laboratory abnormalities for the 
diagnosis of RTD. 
 Regarding the time of patient follow-up, most studies in the literature are meta-
analysis, which mix non-uniform populations, large numbers of variables, dozens of 
comorbidities and old periods of analysis, when RTD was not well defined or 
diagnosed10,13,15,17. 
 A notable feature of this study was the exclusion of patients with detectable HIV 
viral load, avoiding the inclusion of nephropathy associated with direct HIV injury as a 
mechanism for the kidney injury, which would interfere with the results. Furthermore, it 
enabled the analysis of immunity (T-CD4 lymphocyte count) as a risk factor for RTD.  
 Renal tubular injury in this study was defined by the presence of at least one 
alteration analyzed annually in the 24-hour urine (proteinuria, phosphaturia, and/or 
creatinine clearance) and/or hypophosphatemia. Studies defined these alterations as 
tubular abnormalities, ranging from 0 to 5, and showed differences in number to identify 
RTD. The characterization of RTD based on 0 up to 5 tubular alterations leads us to reflect 
that RTD's diagnostic criteria remains undefined. The use of 5 alterations (similar to 




Fanconi syndrome) as a diagnostic criterion stems from outdated studies and reduces 
RTD detection sensitivity. More recent studies have been suggesting the presence of 2 
or more tubular abnormalities for the diagnosis of RTD. However they still do not define 
which alterations are more or less sensitive15,16,18. 
 The prevalence of RTD in this study was 14% (Table 1). This result was also seen 
in other studies, 13.9% until 72%4-6,9,13,15,17. Age was the only risk factor for the 
development of RTD. Annually, the percentage of development of RTD increased in 9% 
(Table 3). The risk of development of RTD in people over 60 year-old was 14-fold (Table 
4). Age is considered a physiological factor for the RTD onset because the natural and 
progressive decrease in renal function and reduction in tubular anion transporter function. 
Some studies have shown age (35.5 to 46.7 years) as a risk factor for DTR development4-
6,9,13-15,17. 
 The risk for a patient with T-CD4 lymphocyte blood count (mean 550 cells/mm3) to 
develop RTD was 72% lower (Table 4). These finding indicates high immunity is a 
protective factor.  
Several researches showed T-CD4 lymphocytes blood count less than 500 cells/ 
mm3 was considered a risk factor for RTD development. However, the afore mentioned 
studies included patients with HIV viral activity (detectable viral load). These approach 
might have weakened the statistical test of the immunity variability without AIDS 
interference. Consequently, immunity could not be considered an influence factor for RTD 
development4,9,13,15. 
Another interesting finding in our study was that the contamination time (mean of 
105 months) was not considered a risk factor for RTD development. Other studies with 
contamination time varying from 88 to 164 months also showed contamination time was 
not considered a risk factor5,6,9,13,14. Conversely, one study with contamination time of 147 
months was considered a risk factor. 
In this study, time on ART with TDF was not a risk factor for RTD development. This 
result might be due to time course of the treatment. Two other studies with time course 
treatment of 9 and 66 months respectively, was considered a determinat factor for RTD 
development. Long term studies are necessary to standardize these variable.   
 Initial serum creatinine (mean 0.88 mg/dL) and current (at RTD diagnosis) serum 
creatinine (mean 0.82 mg/dL) of the patients studied were not considered as risk factors 
for the onset of RTD (Table 6). Studies in the scientific literature do not consider creatinine 
as a risk factor for RTD. Creatinine is a marker for glomerular kidney diseases and should 
not be used for the diagnoses of tubular renal diseases18,19. 
 The initially estimated urine creatinine clearance (mean of 107 mL/min) when 
compared with the current (at RTD diagnosis) creatinine clearance (mean of 114 mL/min) 
did not showed to be a risk factor for the diagnosis of RTD (Table 6). In people free of 
renal disease is expected descrease of 0,4mL/min/year in the estimated urine creatinine 
clearence. In patient under TDF treatment the reduction of 3.92mL/min/year has been 
reported16. 
 Additionally, current (at RTD diagnosis) serum phosphorus should not to be 
considered a variable to diagnose RTD. In our study, only one patient showed 
hypophosphatemia (Tables 7 and 8). Reduction in serum phosphorus from 9% up to 15% 
was reported in other reasearches4,6,19. 




 Increased urine protein concentration in the 24-hour urine indicates RTD. 
Hyperproteinuria was observed in 37.5% (3/8) patients (Tables 7 and 8). Studies reported 
proteinuria as the predominant tubular alteration in diagnose RTD, and its prevalence 
was between 13% and 72%4,6,9,13,15,17. These studies included patients with several 
comorbidities, other nephrotoxic drugs, and HIV patients with detectable viral loads. In ou 
study, patients under those conditions were excluded. Hyperproteinuria should not be 
used valuated alone to diagnose RTD, once it might be found out in other tubular, 
glomerular and non renal diseases18. 
 The most importante variable of RTD was the 24-hour urine phosphate 
concentration. Hyperphosphaturia was observed in 87.5% (7/8) of the patients (Tables 7 
and 8). Hyperphosphaturia  is a specific alteration for renal tubular diseases. Othe studies 
showed hyperphosphaturia occurred in 43% of the patients with RTD. Hypophosphatemia 
has been associated with hyperphosphaturia and suggests the diagnosis of RTD4,6,19. 
Renal tubular dysfunction remains without definitive diagnostic criteria and 
associated risk factors. Meanwhile, the most effective method for diagnosing RTD is to 
perform 24-hour urine test in patients under antiretroviral therapy using TDF once a year 
and finding at least two tubular alterations in this test15,17,18. 
 
CONCLUSION 
 The prevalence of RTD was 14%. Age was considered to be an important risk 
factor for RTD, especially in those patients above 60-year-old. The clinical pathological 
variables that showed the highest diagnostic sensitivity for RTD were phosphaturia and 
proteinuria. Serum creatinine and phosphorus concentration, creatinine clearance and 
hyperproteinuria did not show sensitivity as diagnostic predictors for RTD. 
 Renal tubular dysfunction still remains without diagnostic criteria and definitive risk 
factors. Currently, the most effective method for diagnosis is monitoring 24-hour urine 
annually in patients on ART with TDF and finding at least two tubular alterations in this 
test. The overall risk is mild and corroborates the recommendations of the majority 
international guidelines for the use of TDF as first-line ART for most patients, once that 
they are adequately monitored.  
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